Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer

被引:13
|
作者
Planas, Jacques [1 ]
Celma, Ana [1 ]
Placer, Jose [1 ]
Cuadras, Merce [1 ]
Regis, Lucas [1 ]
Gasanz, Carlos [1 ]
Trilla, Enrique [1 ]
Salvador, Carlos [1 ]
Lorente, David [1 ]
Morote, Juan [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Vall dHebron, Dept Urol, Barcelona, Spain
关键词
Androgen deprivation therapy; castration level; luteinizing hormone; prostate cancer; testosterone; SERUM TESTOSTERONE; CESSATION; AGONIST; TIME; MEN; NORMALIZATION; SUPPRESSION; WITHDRAWAL; CARCINOMA; TRENDS;
D O I
10.1080/21681805.2016.1227876
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of this study was to evaluate hormonal recovery after cessation of androgen deprivation therapy (ADT) in a group of elderly prostate cancer patients. Materials and methods: Forty patients with locally advanced or metastatic prostate cancer, with a mean age of 71.5 years [95% confidence interval (CI) 69.1-73.9], were treated with ADT for a mean duration of 74.6 months (95% CI 59.7-89.5 months). Mean follow-up time after ADT cessation was 36.5 months (95% CI 30.6-42.3 months). Serum testosterone and luteinizing hormone (LH) were determined at 6 month intervals after ADT cessation. Results: After 18 months of follow-up, all patients had recovered normal LH levels, while 38% of patients still presented castration levels of testosterone (< 50 ng/dl). A multivariate analysis was performed to find factors related to testosterone recovery (testosterone >50 ng/dl). Neither age at start of ADT nor clinical stage reached statistical significance. Only time under ADT was correlated with testosterone recovery (p = .031). Kaplan-Meier curves were obtained. Mean time for testosterone recovery was 14.5 months (95% CI 6.5-22.6 months) in patients treated with ADT for less than 60 months compared to 29.3 months (95% CI 19.6-39.1 months) in patients treated with ADT for more than 60 months (log-rank p = .029). Conclusions: Age did not correlate with testosterone recovery in a group of elderly prostate cancer patients in whom ADT was stopped. Testosterone recovery after ADT cessation was significantly correlated with time under ADT treatment. Significant implications related to economic aspects of the dosage schedule may be considered.
引用
收藏
页码:425 / 428
页数:4
相关论文
共 50 条
  • [1] Long-term effects of androgen deprivation therapy in prostate cancer patients
    Basaria, S
    Leib, J
    Tang, AM
    DeWeese, T
    Carducci, M
    Eisenberger, M
    Dobs, AS
    CLINICAL ENDOCRINOLOGY, 2002, 56 (06) : 779 - 786
  • [2] Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy
    Chan, Jeffrey Shi Kai
    Lee, Yan Hiu Athena
    Liu, Kang
    Hui, Jeremy Man Ho
    Dee, Edward Christopher
    Ng, Kenrick
    Satti, Danish Iltaf
    Tang, Pias
    Tse, Gary
    Ng, Chi Fai
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (04)
  • [3] Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer
    Morote, Juan
    Morin, Jacques Planas
    Orsola, Anna
    Abascal, Jose M.
    Salvador, Caries
    Trilla, Enrique
    Raventos, Caries X.
    Cecchini, Lluis
    Encabo, Gloria
    Reventos, Jaume
    UROLOGY, 2007, 69 (03) : 500 - 504
  • [4] Long-term health care costs for prostate cancer patients on androgen deprivation therapy
    Krahn, M. D.
    Bremner, K. E.
    Luo, J.
    Tomlinson, G.
    Alibhai, S. M. H.
    CURRENT ONCOLOGY, 2016, 23 (05) : E443 - E453
  • [5] Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy
    Schulman, C.
    Irani, J.
    Aapro, M.
    BJU INTERNATIONAL, 2012, 109 : 13 - 21
  • [6] Long term androgen deprivation therapy in prostate cancer
    Ockrim, Jeremy L.
    Abel, Paul D.
    BRITISH MEDICAL JOURNAL, 2008, 337 (7673):
  • [7] Quality of Life in Patients with Testosterone Recovery after Long Term Androgen Deprivation Therapy for High Risk Prostate Cancer
    Nabid, A.
    Carrier, N.
    Martin, A.
    Bahary, J.
    Souhami, L.
    Duclos, M.
    Vincent, F.
    Vass, S.
    Bahoric, B.
    Archambault, R.
    Lemaire, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S15 - S16
  • [8] Testosterone recovery after androgen deprivation therapy in localised prostate cancer: Long-term data from two randomised trials
    Nabid, Abdenour
    Carrier, Nathalie
    Vigneault, Eric
    Martin, Andre-Guy
    Bahary, Jean-Paul
    Van Nguyen, Thu
    Vavassis, Peter
    Vass, Sylvie
    Brassard, Marc-Andre
    Bahoric, Boris
    Archambault, Robert
    Vincent, Francois
    Bettahar, Redouane
    Duclos, Marie
    Wilke, Derek
    Souhami, Luis
    RADIOTHERAPY AND ONCOLOGY, 2024, 195
  • [9] Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes
    Ahmadi, Hamed
    Daneshmand, Siamak
    PATIENT-RELATED OUTCOME MEASURES, 2014, 5 : 63 - 70
  • [10] Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer
    Gillessen, Silke
    Templeton, Arnoud
    Marra, Giancarlo
    Kuo, Yong-Fang
    Valtorta, Emanuele
    Shahinian, Vahakn B.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (23) : 1760 - 1770